The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer
ConclusionThere are few head-to-head studies comparing treatments for NSCLC; there are no such studies between the latest generation of drugs. Consequently, ambiguous areas exist due to the lack of comparative studies among the available evidence, preventing the clinician ’s choice of the most effective treatment and risking the patient receiving suboptimal therapy. Simultaneously, the price of the drug cannot be determined correctly, relying only on indirect evaluations from different trials. To dispel this uncertainty, it would be desirable to initiate a process that brings together the demands derived from clinical pr...
Source: European Journal of Clinical Pharmacology - January 20, 2024 Category: Drugs & Pharmacology Source Type: research
Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios.
The remarkable outcomes achieved with neoadjuvant checkpoint inhibitors for patients diagnosed with MSI colorectal cancer hold the potential to revolutionize the treatment landscape in this context. Specifically, the combination of nivolumab plus ipilimumab in colon cancer and dostarlimab in rectal cancer has led to an unprecedented rate of complete pathological and clinical responses. Notably, these responses have been further substantiated by the absence of relapses, with a 0% relapse rate observed during the first year of follow-up. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Alessandro Pastorino, Fabio Catalano, John R. Zalcberg, Alberto Sobrero Tags: Current Perspective Source Type: research
Combined immunotherapy in melanoma patients with brain metastases: a multicenter international study
We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO outside clinical trials. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 18, 2024 Category: Cancer & Oncology Authors: Mario Mandal à, Paul Lorigan, Maria Chiara Sergi, Naima Benannoune, Patricio Serra, Maria Grazia Vitale, Diana Giannarelli, Ana Maria Arance, Eva Munoz Couselo, Bart Neyns, Marco Tucci, Michele Guida, Francesco Spagnolo, Ernesto Rossi, Marcella Occelli, Tags: Original Research Source Type: research
Cancers, Vol. 16, Pages 340: Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
Johnson
Immune checkpoint inhibitors (ICIs) are used to treat many cancers, and cutaneous immune-related adverse events (cirAEs) are among the most frequently encountered toxic effects. Understanding the incidence and prognostic associations of cirAEs is of importance as their uses in different settings, combinations, and tumor types expand. To evaluate the incidence of cirAEs and their association with outcome measures across a variety of ICI regimens and cancers, we performed a systematic review and meta-analysis of published trials of anti–programmed death-1/ligand-1 (PD-1/PD-L1) and anti&ndash...
Source: Cancers - January 13, 2024 Category: Cancer & Oncology Authors: Nina B. Curkovic Kun Bai Fei Ye Douglas B. Johnson Tags: Systematic Review Source Type: research
New | phs003412.v1.p1 | A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab in Stage IV Squamous Cell Lung Cancer
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab in Stage IV Squamous Cell Lung Cancer (study page |release notes) (Source: dbGaP, the database of Genotypes and Phenotypes)
Source: dbGaP, the database of Genotypes and Phenotypes - January 11, 2024 Category: Genetics & Stem Cells Tags: StudyRelease Source Type: research
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
In this study, 22 AILD patients under ICI treatment could be identified. Among these patients, 12 had primary biliary cholangitis (PBC), five had primary sclerosing cholangitis (PSC), four had autoimmune hepatitis (AIH), and one patient had an AIH-PSC variant syndrome. Eleven patients had hepatobiliary cancers and the other 11 patients presented with non-hepatic tumors. The applied ICIs were atezolizumab (n=7), durvalumab (n=5), pembrolizumab (n=4), nivolumab (n=4), spartalizumab (n=1), and in one case combined immunotherapy with nivolumab plus ipilimumab. Among eight patients who presented with grade 1 or 2 irAEs, three d...
Source: Frontiers in Immunology - January 10, 2024 Category: Allergy & Immunology Source Type: research
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
The primary analysis of the phase III NIBIT-M2 study showed a 41% 4-year overall survival (OS) of melanoma patients with asymptomatic brain metastases treated with ipilimumab plus nivolumab. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 10, 2024 Category: Cancer & Oncology Authors: Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Elena Simonetti, Federica Santangelo, Giovanni Amato, Alessia Covre, Roberto Camerini, Monica V Tags: Original Research Source Type: research
Cancers, Vol. 16, Pages 281: Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting
In conclusion, several combination therapies of ICIs and novel strategies are emerging and may revolutionize the treatment paradigm of MSI-H patients in the future. A huge effort will be necessary to find reliable immune biomarkers to personalize therapeutical decisions. (Source: Cancers)
Source: Cancers - January 9, 2024 Category: Cancer & Oncology Authors: Edoardo Crimini Luca Boscolo Bielo Pier Paolo Maria Berton Giachetti Gloria Pellizzari Gabriele Antonarelli Beatrice Taurelli Salimbeni Matteo Repetto Carmen Belli Giuseppe Curigliano Tags: Review Source Type: research
Volumetric growth rate of incidentally found meningiomas on immunotherapy
ConclusionCheck-point inhibitors may impact the natural history of meningiomas. Additional research is needed to define potential clinical indications and treatment goals. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 9, 2024 Category: Cancer & Oncology Source Type: research
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations —Going beyond the body‐size effect
This study approach may be applicable to the optimization of pediatric dosing of other mAbs and possibly other biologics. (Source: CPT: Pharmacometrics and Systems Pharmacology)
Source: CPT: Pharmacometrics and Systems Pharmacology - January 8, 2024 Category: Drugs & Pharmacology Authors: Zheyi Hu,
Sihang Liu,
Yue Zhao,
Shengnan Du,
Lora Hamuro,
Jun Shen,
Amit Roy,
Li Zhu Tags: ARTICLE Source Type: research
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
ConclusionOur study underscores the potential of using myeloid-cell targeted CpG-STAT3 inhibitors for genitourinary cancer therapy to disrupt tolerogenic signaling, restore immune cell activity and sensitivity to immune checkpoint inhibitors and/or T cell-based immunotherapies. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - January 8, 2024 Category: Allergy & Immunology Source Type: research
Cancers, Vol. 16, Pages 250: Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors
uster
Malignant melanoma is a prevalent and aggressive cancer, with globally increasing incidences. While immune checkpoint inhibitors (ICIs) have prolonged the survival of patients with advanced melanoma over the last decade, this improvement comes with the risk of severe immune-related adverse events (irAEs). This systematic review investigates patient baseline characteristics (BCs) as predictive factors for developing severe gastrointestinal, hepatic, and pulmonary irAEs in patients treated with ipilimumab (anti-CTLA-4) and/or nivolumab/pembrolizumab (anti-PD-1). A systematic literature search was conducted in the O...
Source: Cancers - January 5, 2024 Category: Cancer & Oncology Authors: Kremena Petrova Trichkova Franziska G örtler Line Bj ørge Cornelia Schuster Tags: Systematic Review Source Type: research
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
ConclusionsReal-world data suggests that NICT could be a favorable treatment option compared with PCT for patients with advanced NSCLC. Further follow-up is needed to determine the long-term prognostic benefit. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - January 4, 2024 Category: Cancer & Oncology Source Type: research
Current Trends and Future Directions of Malignancy After kidney Transplantation: A 1970-2022 Bibliometric Analysis
CONCLUSIONS The focus of MKT-related studies has evolved from exploring the spectrum, risk factors, and outcomes of MKT, to examining the pathogenesis, individualized screening, prevention, and treatment, including appropriate use of immune checkpoint inhibitors. Reports of renal transplant recipients infected with SARS-CoV-2 or COVID-19 have also gained attention since 2019. These suggest that individualized management remains a frontier for research and a future direction in MKT topics.PMID:38163947 | DOI:10.12659/AOT.942074 (Source: Annals of Transplantation)
Source: Annals of Transplantation - January 2, 2024 Category: Transplant Surgery Authors: Fan Jiang Fang Wang Tianyu Zhang Hongmei Dong Hongwei Bai Liping Chen Source Type: research
